Shaping the Future of Dermatology With Insights From AAD 2025 and Beyond

Image Credit: © kwanchaift - stock.adobe.com

This year’s American Academy of Dermatology (AAD) Annual Meeting delivered a wealth of insights, from late-breaking research to expert discussions on emerging therapies. Dermatology Times was onsite to capture key takeaways, including advancements in skin cancer treatment, updates on inflammatory skin disease management, and evolving trends in aesthetic dermatology.

Our latest issue features in-depth coverage of AAD highlights alongside exclusive interviews with leading key opinion leaders. We also spotlight promising therapeutic developments presented at the meeting, including long-term data for risankizumab and bimekizumab in psoriasis, patient outcomes with nonsteroidal tapinarof in atopic dermatitis, and more.

Dermatology Times’ Editor-in-Chief Christopher Bunick, MD, PhD, reflects on critical advancements following AAD, highlighting the critical focus on patient safety, regulatory standards, and the ongoing evolution of therapeutic options. Through his reflections, Bunick emphasizes the need for a collaborative approach in fostering innovation, enhancing care, and ensuring the highest safety standards in dermatology.

This month’s cover feature focuses on Rosacea Awareness Month with expert insights from the National Rosacea Society and the American Acne & Rosacea Society, shedding light on patient care and evolving treatment paradigms. James Del Rosso, DO, and Zoe Diana Draelos, MD, provide in-depth perspectives on the latest advancements, including low-dose oral minocycline and lotilaner for ocular rosacea. Looking forward, emerging studies on the gut-skin axis and microbiome modulation offer promising avenues for more targeted, long-term treatment solutions for patients.

Additionally, we explore clinical considerations for managing acne in menopause, including the impact of hormonal changes, treatment options, and personalized skin care approaches for this patient population.

As always, Dermatology Times delivers the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert perspectives. Stay informed with the latest data— subscribe to Dermatology Times’ e-newsletters, follow us on Facebook, LinkedIn, and X (formerly Twitter), and reach out with ideas or contributions to DTEditor@mmhgroup.com.